Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives $366.00 Consensus PT from Analysts
Bio-Rad Laboratories, Inc. (NYSE:BIO) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $366.00.
Several equities analysts have issued reports on BIO shares. ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. Barclays reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 9th. Deutsche Bank downgraded shares of Mitsubishi Motors from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, Zacks Investment Research downgraded shares of W. R. Grace & Co from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.
In other news, EVP Timothy S. Ernst sold 345 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $290.00, for a total value of $100,050.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 27.84% of the company’s stock.
NYSE BIO traded up $3.12 during mid-day trading on Monday, reaching $312.35. 179,719 shares of the stock were exchanged, compared to its average volume of 218,405. The business has a 50 day simple moving average of $300.60. Bio-Rad Laboratories has a 1 year low of $220.05 and a 1 year high of $345.15. The stock has a market cap of $9.22 billion, a P/E ratio of 53.48, a P/E/G ratio of 2.88 and a beta of 1.22. The company has a quick ratio of 3.24, a current ratio of 4.57 and a debt-to-equity ratio of 0.13.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported $1.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.53. The business had revenue of $553.98 million for the quarter, compared to the consensus estimate of $548.82 million. Bio-Rad Laboratories had a net margin of 24.84% and a return on equity of 4.15%. Equities analysts forecast that Bio-Rad Laboratories will post 7.15 EPS for the current year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Read More: Cost of Goods Sold (COGS)
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.